Research & Development: Page 34
-
PharmaVoice Team/PharmaVoice
Speak Out: Making Data Central to Your CNS and Pain Trials
A Therapeutic-Area-Specific Approach to Data Capture Solutions For data capture, CNS and pain trials are demanding, with complicated eligibility criteria, extensive monitoring requirements, comprehensive data collection, and substantial demands on patients. To design a great solution, we consulte...
By Kyle Hogan • Nov. 16, 2020 -
PharmaVoice Team/PharmaVoice
Upfront
Takeda’s Innovators in Science Award Takeda Pharmaceuticals and the New York Academy of Sciences are drawing attention to the urgent needs of patients worldwide affected by an estimated 7,000 rare diseases. The 2020 Innovators in Science Award recognizes scientists from around the globe for their...
By PharmaVoice Team • Oct. 1, 2020 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
HealthTech
Organ-on-a-Chip Transforms Drug Development Trend Watch: Healthtech Applications Run the Gamut from Chip Technology to EHRs, to Electronic Skin and Clinical Trials Draper’s Ex Vivo Immuno-oncology Dynamic Environment for Tumor biopsies (EVIDENT) is a microfluidic platform that maintains tumor fra...
By PharmaVoice Team • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
Case Study: Leveraging AI for Meaningful Clinical Trials
Clinical trial sponsors seeking to develop new drugs and therapies face unique challenges, particularly when it comes to understanding patient dosing and response to therapy. This aspect can be difficult, as patients often: Do not take their medicine regularly, or at all Take creative measures to...
By Rich Christie • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
AI and Drug Discovery
Discovering and bringing new drugs to market is notoriously slow and costly for a reason. Science moves slowly because of the incredibly complex nature of human biology and the difficulty of sluggish recruitment of clinical trials. And in spite of greater investments in R&D by pharmaceutical ...
By Claire Bonaci • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
The Accessibility of AI: Innovation at Your Fingertips
The availability of datasets keeps growing exponentially. With this we are witnessing an escalation of available new life-altering systems. Some of these tools are highly autonomous and can perform functions with little to no human intervention. Self-driving cars, rockets that land upright on dro...
By Max Divak • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
Site Unseen? Virtual and Hybrid Trials the Way of the Future
Decentralized trials create new opportunities for reaching more patients and safeguarding them during a pandemic, but what do they mean for sites? The clinical trial landscape has been going through a period of rapid and profound change. Even before the COVID-19 pandemic, trial sites have faced m...
By Kim Ribbink • Oct. 1, 2020 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
Turning on the Switch Fulcrum’s proprietary product engine identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. Bringing more than 30 years of R&D experience to his role as president and CEO of Fulcrum Therapeutics, Robert Gould, Ph....
By Robert Gould • Sept. 1, 2020 -
PharmaVoice Team/PharmaVoice
Turning Data into Storytelling
Beyond communications skills, creating a good data story requires research. Nobody wants to listen to a boring story. And for some, data can be boring, or at best, confusing. Telling an enthralling story takes a certain skill, and when the topic is a mound of eye-glazing data and analysis, it bec...
By Robin Robinson • Sept. 1, 2020 -
PharmaVoice Team/PharmaVoice
Commanders & Chiefs: Chief Medical Officers
Chief Medical Officers have a big remit when it comes to overseeing their organization’s clinical trial strategies as well as keeping the patient voice top of mind. Dr. David Andrews Tracking Neo-Antigens The biggest trend in the immuno-oncology space is the pursuit of a successful solid tumor im...
By PharmaVoice Team • Sept. 1, 2020 -
PharmaVoice Team/PharmaVoice
Mentors
These champions of diversity and inclusion are dedicated to developing the next generation of leaders and setting an example for others to follow. An Ally for All Raising the bar… by bringing people together Peter Anastasiou Title: Executive VP & Head of North America Company: Lundbeck Indust...
By PharmaVoice Team • Aug. 1, 2020 -
PharmaVoice Team/PharmaVoice
Technologists
Big data and technology are key drivers of future innovation in the industry, and these leaders are always looking forward to the next big idea. Creating a Digital Health Transformation Raising the bar… by delivering solutions that reach from bench to bedside Rama K. Kondru, Ph.D. Title: Executiv...
By PharmaVoice Team • Aug. 1, 2020 -
PharmaVoice Team/PharmaVoice
SHOWCASE: Clinical Trial Solutions: Improving Trials with Technology
Technology is taking center stage as a way to mitigate clinical challenges and improve patient outcomes. The clinical trials market is massive and continues to grow. According to a report from Grand View Research, the global clinical trials market will be worth $65.2 billion by 2025. At the same...
By PharmaVoice Team • June 1, 2020 -
PharmaVoice Team/PharmaVoice
Effective Design and Implementation of Sponsor/CRO Governance — Reducing Risk While Enhancing Transparency
Governance board meetings have always been an important venue to ensure quality and maintain a healthy and productive relationship between sponsors and CROs. As the demands of the clinical research industry continue to evolve with a pandemic now amongst us, the need for effective program governan...
By Melissa Mauriber • June 1, 2020 -
PharmaVoice Team/PharmaVoice
Virtual Trials: The Silver Lining of the COVID-19 Pandemic
Many of us are identifying the proverbial silver linings associated with the changes we have been forced to make in response to the COVID-19 pandemic. One rather sweeping silver lining is the increased and accelerated use of technology in both our business and personal lives, with an obvious exam...
By Jim Mahon • June 1, 2020 -
PharmaVoice Team/PharmaVoice
How COVID-19 Changed the Way We Recruit
Amplifying the need for a new era of strategic patient recruitment and retention. The need for rapid and adaptive recruiting strategies has never been more urgent than in response to COVID-19. This pandemic is pushing those working to develop new treatments to pursue more agile and innovative str...
By Erica Prowisor • June 1, 2020 -
PharmaVoice Team/PharmaVoice
Real-World Data for R&D
Developing a much-needed new therapeutic, maybe even for Covid 19? Seeking approval to expand labeling for an existing treatment? Wanting to understand the standard of care, design a trial, create a comparator cohort, identify a new biomarker, or model patients most likely to benefit from a parti...
By Richard Gilklich • June 1, 2020 -
PharmaVoice Team/PharmaVoice
Leveraging Remote Monitoring to Increase Safety, Results and Efficiencies During the Pandemic and Beyond
In 2020, the phrase “clinical trial solutions" takes on a new — and more relevant — meaning than ever before. The world needs a solution to the global COVID-19 pandemic, and we in the life-sciences industry can contribute to that solution through innovative, state-of-the-art technology that enabl...
By Gergory T. Simpson • June 1, 2020 -
PharmaVoice Team/PharmaVoice
Age of the Machine: Using Algorithms to Advance Outcomes
Machine learning is being applied across the industry to support decision-making in clinical trials, R&D, regulatory, and commercial processes. What’s the difference between machine learning and artificial intelligence? The answer lies in the word intelligence, since AI is about enabling mach...
By Kim Ribbink • June 1, 2020 -
PharmaVoice Team/PharmaVoice
Executive Perspective: Transforming the Clinical Experience As a Digital Care Option for Patients — A New Age of Care
A Conversation with MaryAnne Rizk, Ph.D. For MaryAnne Rizk, Ph.D., Senior VP, Digital R&D Strategy at IQVIA, improving the patient experience is more than a calling; it’s a passion. She is driven by an inherent desire to improve the quality of life for patients. Her particular area of experti...
By Mary Ann Rizk • June 1, 2020 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
The sequelae The personal, economic, and cultural upheaval from the coronavirus tragedy has changed our lives. The numbers, which during the early days of reported cases were abstract for most of us, have taken on new meaning in the subsequent months, as most of us now know someone who has contra...
By Taren Grom • May 1, 2020 -
PharmaVoice Team/PharmaVoice
Changing Health Outcomes with Digital Twins
While the digital twin is not yet widely used in the pharmaceutical industry, the concept has huge potential across R&D and manufacturing. A decades-old technology is coming of age in the life-sciences industry, bringing with it the potential to solve many of the challenges companies continue...
By Kim Ribbink • May 1, 2020 -
PharmaVoice Team/PharmaVoice
Women of Influence
Leaders become great, not because of their power, but because of their ability to empower others – John Maxwell More than two dozen women who sit in seats of influence are using their talents, strategic acumen, and tenacity to create change throughout the life-sciences industry and their organiza...
By PharmaVoice Team • April 1, 2020 -
PharmaVoice Team/PharmaVoice
Upfront
Teva and Direct Relief Partner to Bring Cancer Medicines to Africa Global HOPE (Hematology-Oncology Pediatric Excellence), a program of Texas Children’s Hospital, Teva Pharmaceutical Industries, and Direct Relief are partnering to provide access to medications in sub-Saharan Africa, where a major...
By PharmaVoice Team • March 1, 2020 -
PharmaVoice Team/PharmaVoice
Patient-Enhanced Drug Discovery and Development
Patients are uniquely positioned to inform the understanding of the therapeutic context for drug development and evaluation. In other industries, it would seem odd not to get input from the end user of a product throughout the development stages. But it seems that pharmaceutical companies — some ...
By Taren Grom • March 1, 2020
Previous
